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Decreased susceptibility of Neisseria meningitidis iso-
lates to ciproﬂ  oxacin emerged from an outbreak in Delhi, In-
dia. Results of antimicrobial susceptibility testing of the me-
ningococcal isolates to ciproﬂ  oxacin and further sequencing 
of DNA gyrase A quinolone-resistance–determining region 
conﬁ  rmed the emergence of ciproﬂ  oxacin resistance in the 
outbreak.
N
eisseria meningitidis serogroup A is the major cause 
of meningitis outbreaks worldwide, especially in Af-
rican and Asian countries, including India. Meningococcal 
disease is endemic in India, and sporadic cases of meningo-
coccal meningitis have occurred in Delhi in previous years 
(1). During 1966, 616 cases of meningitis were reported; 
case-fatality rate was 20.9%. In 1985, an outbreak of greater 
magnitude had 6,133 cases with 799 deaths (13%). An out-
break of meningococcal meningitis also occurred in Delhi 
during April–July 2005 (1), and the disease reappeared in 
January–March 2006.
When a sporadic case or epidemic occurs, the close 
contacts need to receive a vaccine and chemoprophylaxis 
with antimicrobial drugs to cover the delay between vac-
cination and protection. Recently, ciproﬂ  oxacin and cef-
triaxone have been established as acceptable alternatives 
to rifampin for prophylaxis of meningococcal disease (2). 
Because ciproﬂ  oxacin can be used in single doses during 
meningococcal epidemics, ciproﬂ  oxacin is the chemopro-
phylactic agent of choice (3). Because meningococcal dis-
ease is a serious and rapidly progressing illness, monitor-
ing the trends in the resistance to antimicrobial agents is 
important. To date, ciproﬂ  oxacin-resistant serogroup A N. 
meningitidis has not been reported anywhere in the world. 
Four reports of sporadic instances of decreased susceptibil-
ity to ciproﬂ  oxacin: serogroup B from France in 1999 and 
Spain in 2002, serogroup C from Australia in 1998, and se-
rogroup Y from Argentina in 2002 (4–6). For the ﬁ  rst time, 
to our knowledge, we report the emergence of decreased 
susceptibility of serogroup A N. meningitidis to ciproﬂ  oxa-
cin from the 2005 outbreak in Delhi.
The Study
A total of 444 meningococcal cases and 62 deaths due 
to meningococcal meningitis serogroup A were reported in 
Delhi during April–July 2005. The reappearance of menin-
gococcal cases was reported in Delhi during January–March 
2006 (177 meningococcal cases and 17 deaths). The me-
ningococcal cases were reported from the major hospitals 
and were characterized by sudden onset of fever with pete-
chial rash, neck stiffness, and altered sensory functions. All 
age groups were affected, but the highest proportion was in 
those 15–30 years of age; male patients accounted for 71% 
of cases and female patients 29%.
Fourteen N. meningitidis clinical isolates were collect-
ed from the major hospitals in Delhi. All these isolates were 
from patients with meningococcal meningitis from the out-
break. The strains were isolated mainly from cerebrospinal 
ﬂ  uid and a few from skin swabs; the primary culture, isola-
tion, and serogrouping (Latex agglutination kit, Wellcogen, 
Wellcome, Dartford, UK) were performed in the respec-
tive hospitals. N. meningitidis strains from Ranbaxy Re-
search Laboratories culture collection (RRL-1 and RRL-2) 
were used as reference serogroup A strains. In addition, 11 
clinical isolates collected during the January–March 2006 
recurrent outbreak were also included for selective antimi-
crobial drug susceptibility testing in this study.
The MICs of antimicrobial agents against these iso-
lates were determined by the agar dilution method on 
Mueller-Hinton agar plates with 5% sheep blood as rec-
ommended by Clinical and Laboratory Standard Institute 
(CLSI) guidelines (7). The pulsed-ﬁ  eld gel electrophoresis 
(PFGE) method used in this study was based on the proce-
dures described by Popovic et al. (8). Two isolates (Ap-II 
420 and Ir-I 442) from the outbreak were used for genotyp-
ing as described by Maiden et al. (9) and analyzed by using 
the multilocus sequence typing (MLST) database (10).
Because the N. meningitidis isolates showed resistance 
to ciproﬂ  oxacin, the DNA gyrase A quinolone-resistance–
determining regions (QRDRs) of 2 ciproﬂ  oxacin-sensitive 
and 7 ciproﬂ  oxacin-resistant meningococcal strains from 
this outbreak and 2 reference strains were sequenced. The 
following primers were used for QRDR study. The forward 
primer was 5′-CGTACTGTACGCGATGCACGA-3′; the 
reverse primer was 5′-TTTCGCCATGCGGATTTCGGT-
3′. The genomic DNA was isolated from the strains and 
PCR was performed as described by Shultz et al. (11).
The MIC pattern of the clinical isolates of N. menin-
gitidis from the outbreak showed that they were susceptible 
1614  Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 13, No. 10, October 2007
*Ranbaxy Research Laboratories, Gurgaon, India; †Vardhman Ma-
haveer Medical College and Safdarjung Hospital, New Delhi, India; 
‡Ministry of Health and Family Welfare, New Delhi, India; §National 
Institute of Communicable Diseases, Delhi, India; and ¶Caribbean 
Epidemiology Centre, Port of Spain, Trinidad and Tobago Ciproﬂ  oxacin-Resistant Neisseria meningitidis, India
to β-lactam antibiotics penicillin, ampicillin, and a third-
generation cephalosporin, ceftriaxone. The MIC against 
ceftriaxone for all the clinical N. meningitidis isolates was 
<0.001 μg/mL. Of 14 strains, 12 showed decreased suscep-
tibility to all the ﬂ  uoroquinolones, especially to ciproﬂ  oxa-
cin (MIC 0.25 μg/mL) (online Appendix Table, available 
from www.cdc.gov/EID/content/13/10/1614-appT.htm). In 
addition, all these 12 strains were resistant to nalidixic acid 
(MIC >16 μg/ml). A notable shift in antimicrobial suscep-
tibility was not observed in these isolates against protein 
synthesis inhibitors (Online Appendix Table). Eleven me-
ningococcal isolates from the recurrent outbreak showed 
resistance to ciproﬂ  oxacin as well as nalidixic acid (Table). 
The break points are based on the CLSI guidelines (7).
The PFGE patterns of the strains from the outbreak 
(9 strains) were indistinguishable, and they appeared to be 
from the same origin (Figure 1). The antimicrobial drug 
resistance patterns were not distinguishable from the PFGE 
types. The PFGE pattern of the strains from the outbreak 
was different from that of the reference strains RRL-1 and 
RRL-2. The housekeeping genes of the ciproﬂ  oxacin-re-
sistant strain (Ir-I 442) showed no alteration or mutation, 
and they were identical to the ciproﬂ  oxacin-sensitive strain 
(Ap-II 420). Neisseria MLST analysis with the MLST data-
base showed that these isolates were similar to the outbreak 
strains from Dhaka, Bangladesh (2002), and Nigeria (2003) 
(10). In addition to the endemicity in Delhi, the migration 
of persons or visitors from other countries may have con-
tributed to the spread of the serogroup A outbreak.
The sequencing of the gyrA QRDRs of ciproﬂ  oxacin-
resistant strains of N. meningitidis showed 4 amino acid 
differences. One of these encoded a conservative threo-
nine substitution at position 91 (Thr-91 → Ile); the other 
3 changes were synonymous: Asn-103 → Asp, Ile-111 
→ Val, and Val-120 → Ile (Figure 2). Gyrase A changes 
have been reported in clinical isolates of resistant menin-
gococci in positions 91 (Thr-91 → Ile) and 95 (Asp-95 → 
Asn and Asp-95 → Gly) (4–6). The N. meningitidis gyrA 
gene shares 95% identity with the N. gonorrhoeae gyrA 
gene. The GyrA substitution in meningococci at position 
91 (Thr-91 → Ile) was equivalent to Ser-91 → Ile, reported 
in  ﬂ  uoroquinolone-resistant N. gonorrhoeae from Japan 
(12). In meningococci as well as in gonococci, the muta-
tion at position 91 causes ﬂ  uoroquinolone resistance. For 
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Table. Antimicrobial susceptibility pattern of Neisseria meningitidis isolates from the recurrent outbreak during January– March 2006, 
Delhi, India* 
MIC (μg/mL)
Isolate PEN CRO RIF CIP GAT MXF LVX SPX NOR NAL
SFDJ M-1  0.125 0.008 0.004 0.125 0.03 0.125 0.125 0.06 0.125 >16
SFDJ M-2 0.125 0.008 0.004 0.25 0. 25  0.125 0.03 0.06 0.25 >16
SFDJ 691  0.03 <0.001 0.125 0.25 0.25 0.5 0.25 0.25 0.5 >16
SFDJ 306  0.03 0.008 0.008 0.125 0.06 0.125 0.25 0.06 0.25 >16
SFDJ 651  0.06 0.002 0.03 0. 5  0.125 0.25 0.25 0.125 0.5 >16
SFDJ 568 0.125 0.002 0.06 0.25 0.125 0.25 0.25 0.125 0.5 >16
SFDJ 668 0.06 0.002 0.06 0.25 0.125 0.25 0.125 0.125 0.25 >16
SFDJ 270 0.125 0.008 0.015 0.125 0.06 0.125 0.125 0.125 0.25 >16
SFDJ  MA-3 0.06 0.004 0.125 0.5 0.25 0.25 1 1 1 >16
SFDJ 339  0.125 <0.001 0.25 0.25 0.25 0.25 0.25 0.25 0.25 >16
SFDJ 58 0.125 0.008 0.004 0.125 0.06 0.125 0.03 0.06 0.25 >16
*PEN, penicillin; CRO, ceftriaxone; RIF, rifampin; CIP, ciprofloxacin; GAT, gatifloxacin; MFX, moxifloxacin; LVX, levofloxacin; SPX, sparfloxacin; NOR, 
norfloxacin; NAL, nalidixic acid. 
Figure 1. Pulsed-ﬁ   eld gel electrophoresis (PFGE) pattern of the 
Neisseria meningitidis isolates from the outbreak. The chromosomal 
DNA digested with SpeI enzyme was separated by clamped 
homogeneous electric ﬁ  elds PFGE (BioRad, Hercules, CA, USA). 
1, RRL-1; 2, RRL-2; 3, SFDJ 723; 4, Ap-II 420; 5, SFDJ E-95; 6, 
IR-I 442, 7, IR-II 440; 8, SFDJ E-100; 9, SFDJ 184; 10, SFDJ E-79; 
11, NICD 18. DISPATCHES
example, 1 N. meningitidis strain from 2005 outbreak, IR-II 
440, showed the mutation only at position 91 (Thr-91 → 
Ile), and ciproﬂ  oxacin resistance was observed.
Conclusions
The antimicrobial drug susceptibility of the clinical 
isolates and further sequencing of the QRDRs of gyrase 
A of the strains conﬁ  rms the emergence of ciproﬂ  oxacin 
resistance in the outbreak in Delhi. In addition to chemo-
prophylaxis, ﬂ  uoroquinolone consumption in the commu-
nity, for a range of infections may be, in part, responsible 
for the emergence of ciproﬂ  oxacin resistance in N. menin-
gitidis isolates. Lack of N. gonorrhoeae isolate response 
to ciproﬂ  oxacin has been reported in Delhi (13). Drift in 
susceptibility of N. gonorrhoeae to ciproﬂ  oxacin caused 
therapeutic failure. Ciproﬂ  oxacin treatment failure in cases 
of typhoid fever has also been reported (14). To date, to our 
knowledge, no failure of ciproﬂ  oxacin as chemoprophylax-
is for N. meningitidis has been reported. To predict clinical 
outcome, further detailed pharmacokinetic/pharmacody-
namic (PK/PD) analysis is needed to determine the impact 
of the PK/PD parameters on resistance selectivity (15).
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Figure 2. Comparison of GyrA quinolone-resistance–determining region (QRDR) for the alteration of amino acids in Neisseria meningitidis 
isolates. GyrA QRDR 1, ciproﬂ  oxacin-sensitive strains RRL-1, RRL-2, SFDJ 723, Ap-II 420; GyrA QRDR 2, ciproﬂ  oxacin-resistant strains 
SFDJ E-100, SFDJ E-79, SFDJ E-63, NICD 18, SFDJ E-95, IR-I 442; GyrA QRDR 3, ciproﬂ  oxacin-resistant strain IR-II 440. Ciproﬂ  oxacin-
sensitive RRL-1 and RRL-2 were the reference strains, and the other 9 strains were from the outbreak. The shaded positions of the 
amino acids denote changes in GyrA QRDR of ciproﬂ  oxacin-resistant N. meningitidis in Thr-91 → Ile, Asn-103 → Asp, Ile-111 → Val, and 
Val-120 → Ile. The mutation of amino acid at conservative position 91 (Thr-91 → Ile) is responsible for the decreased susceptibility to 
ﬂ  uoroquinolones, and the other 3 changes are synonymous.